Peginterferon α-2b・Ribavirin 併用療法におけるHCV-RNA早期陰性化例に対する短期延長投与の有用性

概要

論文の詳細を見る
Regimen of peginterferon alpha 2b plus ribavirin (PEG/R) for chronic hepatitis C patients could be tailored according to how early HCV viremia disappears after initiation of the treatment. We focused on patients who showed rapid or early virological response: i.e., HCV in serum turned undetectable at week 4 (rapid virological response, RVR), or at week 8-12 (early virological response, EVR). The patients with RVR (n=4) received PEG/R for 48 weeks, while the patients with EVR (n=28) received PEG/R for 52 weeks (in those with VR at week 8) or for 56-60 weeks (in those with VR at week 12), resulting in that 4 of the RVR patients (100%) and 22 of the EVR patients (78.6%) acquired sustained virological response (SVR). The rate of SVR in EVR patients was higher than that so far reported for patients who received the standard 48-week regimen of PEG/R treatment. Meanwhile, the RVR patients showed a satisfactory SVR rate even with the 48-week regimen. Thus our present results suggest that the duration of PEG/R treatment should depend on how early the virological response occurs in the concerned patient.
社団法人　日本肝臓学会の論文
2007-07-25